

Pfizer Oncology Innovation Day Highlights

Accelerate breakthroughs that help people with cancer globally live better and longer lives



175 years
of delivering
breakthroughs
that change
patients' lives



Expertise

Best of both organizations, with exceptional talent and extensive experience

Innovation

Robust R&D engine and pipeline, focused on execution and next-generation breakthroughs

Scale

New organization with industry leading commercial and manufacturing capabilities



Pioneers of ADC
technology to
improve and
extend lives of
people with
cancer

2030 Oncology Goals

2x
patients reached

8+
blockbuster
medicines

~65%
proportion of
business from
biologics compared
to ~6% in 2023

“With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients. With the energy of our highly talented colleagues, the tremendous potential of our pipeline and scientific engine, and scale of the Pfizer enterprise, we believe we are poised to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.”

Chris Boshoff, MD PhD


Chief Oncology Officer & EVP, Pfizer

Oncology Strategy to Drive Long-Term Sustainable Growth

Modality Focus

Enabled by deep technical expertise

Unique ability to combine and adapt modalities to improve outcomes




Small Molecules

World-class structure-guided drug discovery and medicinal chemistry expertise



Antibody-Drug Conjugates (ADCs)

Next-gen platform aimed at novel targets; improved and differentiated payloads




Bispecific Antibodies

IO biologics leading with bispecific antibodies, leveraging protein engineering and antibody design

Therapeutic Area Focus

Building on established presence

Deepen our ability to address unmet medical needs across care continuum




Breast

Across subtypes



Genitourinary

Prostate Cancer
Urothelial Cancer



Hematology-Oncology

Multiple Myeloma
Lymphoma



Thoracic

Non-Small Cell Lung Cancer
Head & Neck Cancer

Accelerating New Standards of Care

IO, immuno-oncology

Powering Into A New Era Of Oncology Leadership


Key Medicines Today



CD30-DIRECTED
ADCETRIS
brentuximab vedotin | for injection



IBRANCE
palbociclib | 125 mg capsules



Xtandi
(enzalutamide)
40 mg tablets | 80 mg tablets



TALZENNA
talazoparib | capsules



PADCEV
enfortumab vedotin-eflv
injection for IV infusion (30 mg & 60 mg vials)



LORBENA
LORLATINIB | tablets



ELREXFIO
(elranatamab-bcmn)
injection for IV infusion (100 mg & 200 mg vials)

A Strong Track Record

Expanded Portfolio of Breakthrough Medicines

2.3M²

Patients treated in 2023

PFE +19% revenue CAGR

Oncology Products from 2014 – 2023

Industry average: 10%¹

Rapidly Delivering Transformational Medicines



First in human to approval

4.8 years



Pivotal start to approval

2.5 years



Top-line results to approval

2.8 months



for 8 cancer indications

8 approvals
in last 3 years⁴

Accelerating Tomorrow's Breakthroughs

49

clinical development programs ongoing

>60

discovery programs

Data published by CMR. Fifteen major companies are participating in the Clinical Study Consortium in 2022; this figure was 18 in 2015. Companies in scope are major companies spending greater than \$2.0B on R&D. A "top 3" position is considered industry leading for study-level cycle time measures given minor fluctuations in company scores. Industry Best reflects the median values of the top 3 performing companies in the industry.

Deep and Diverse Pipeline Within Focused Therapeutic Areas

	Breast	Genitourinary	Hematology-Oncology	Thoracic
Select approved products	IBRANCE palbociclib TUKYSA tucatinib	PADCEV enfortumab vedotin-eflv Xtandi (enzalutamide) TALZENNA + Xtandi talazoparib (enzalutamide)	ELREXFIO enfortumab vedotin-eflv Bosulif bosutinib BESPONSA beximurtinib	LORBENA LORLATINIB tablets XALKORI crizotinib
Select clinical pipeline	Atirmociclib ⁵ (CDK4i) Vepdegestrant ⁵ (PROTAC ER degrader) Felmetatug vedotin ⁶ (B7H4) Disitamab vedotin ⁶ (HER2) KAT6i ⁵ CDK2i ⁵ (PF-0724414) (PF-07104091)	Sasanlimab ⁷ (PD-1) Disitamab vedotin ⁶ (HER2) Mevrometostat ⁵ (EZH2)	Maplirpaccept ⁷ (CD47 SIRPα) CD70 ⁷ (PF-08046040) CD30 ⁶ (PF-08046045)	Sigvatatug vedotin ⁶ (iB6) PD-L1 ^{6,10} (PF-08046054) CEACAM5 ⁶ (PF-08046050) EGFR ^{7,10} (PF-08046052)

Selected preclinical pipeline (FIP anticipated in 2024): STING^{5,8}, LILRB1/2/3, αLTβR^{7,9}, mesothelin-TOPO1⁶, CD30-TOPO1^{6,8}

Key Oncology Catalysts Anticipated Through 1H 2025

Commercial	Phase 3 Data Readouts	Phase 3 Study Starts	Early-Stage Pipeline
PADCEV launch LA/mUC (EV-302) XTANDI launch nmCSPC with high-risk BCR (EMBARK) TALZENNA + XTANDI launch 1L mCRPC (TALAPRO-2) ELREXFIO launch TCR MM	Vepdegestrant 2L ER+ mBC (VERITAC-2) BRAFTOVI 1L BRAF CRC (BREAKWATER) Sasanlimab NMIBC (CREST) ELREXFIO DCE MM (MagnetisMM-5) IBRANCE HER+ mBC (PATINA) TALZENNA + XTANDI Overall survival (TALAPRO-2) Disitamab vedotin ¹¹ 2L+ HER2+/low mUC	Atirmociclib 2L HR+/HER2- mBC ✓ Sigvatatug vedotin 2L-3L NSCLC ✓ ELREXFIO 2L+ post-CD38 MM ✓ Mevrometostat + XTANDI post-abiraterone mCRPC Mevrometostat + XTANDI treatment-naïve mCRPC Atirmociclib 1L HR+/HER2- mBC	FIP of 8+ NMEs across small molecules and biologics, including 4 ADCs Key data readouts PD-L1 and B7H4 ADCs

ADC, antibody-drug conjugate; BCR, biochemical recurrence; CRC, colorectal cancer; DCE, dynamic contrast-enhanced; H, half; HR+, hormone receptor-positive; LA, locally advanced; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; MM, multiple myeloma; mUC, metastatic urothelial carcinoma; nmCSPC, non-metastatic castration-sensitive prostate cancer; NME, new medical entity; NMIBC, non-muscle invasive bladder cancer; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed cell death-ligand 1; TCR, triple class refractory.

Additional Pivotal Readouts Anticipated 2H 2025 and Beyond to Drive Longer-Term Sustainable Growth

Genitourinary	TALZENNA HRRm mCSPC	Mevrometostat mCRPC post-abiraterone	Mevrometostat mCRPC treatment-naïve	Disitamab vedotin 1L HER2+ mUC	PADCEV Cis-eligible MIBC	PADCEV Cis-ineligible MIBC
Thoracic	Sigvatatug vedotin 2L NSCLC	Sigvatatug vedotin 1L NSCLC				
Breast	TUKYSA 1L HER+ maint. mBC	Atirmociclib 2L HR+ / HER2- mBC	TUKYSA HER+ 2L / 3L mBC	TUKYSA HER+ adj. BC	Atirmociclib 1L ER+ / HER2- mBC	Vepdegestrant + atirmociclib / IBRANCE 1L ER+ / HER2- mBC
Hematology-Oncology	ELREXFIO 2L+ post-CD38 MM	ELREXFIO NDMM PTM	ELREXFIO NDMM TI			

Anticipated readouts 2H 2025-2030. Sequence of readouts may differ from slide presentation due to event-driven nature of studies. Additional potential readout includes TUKYSA® (MOUNTAINEER-03) in 1L HER2+ mCRPC.
 1. Evaluate Pharma. CAGR, compound annual growth rate.
 2. Includes Pfizer Oncology and Pfizer Hospital Unit sterile injectables / cytotoxics; excludes legacy Seagen products. Nearly 1M patients treated with Pfizer Oncology Innovative Medicines and Biologics. Patient counts are estimates derived from multiple data sources. Please see the Appendix slide in Pfizer's Oncology Innovation Day presentation for additional information.
 3. Working towards achievement of these goals, which are subject to, among other things, clinical trial, regulatory and commercial success and availability of supply.
 4. Approved medicines: ELREXFIO™ (NME, MM), BRAFTOVI®, MEKTOVI®, TALZENNA®, XTANDI®, ADCETRIS®, PADCEV®, TUKYSA®, and TIVDAK®. CMR, Center for Medicines Research; MM, multiple myeloma; NME, new medical entity.
 5. Small molecule
 6. Antibody-drug conjugate
 7. Immuno-oncology biologic including bispecific antibodies.
 8. IND cleared
 9. IND submitted
 10. Also being explored across multiple solid tumors.
 11. Registration-intent Phase 2 trial

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects, including Pfizer's 2030 oncology goals; expectations for Pfizer's product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity, expected breakthrough, best- or first-in-class or blockbuster status; or expected market entry of our medicines, and potential benefits, potential patients reached; potential portfolio composition; plans for and prospects of our acquisitions, dispositions and other business development activities, including our recent acquisition of Seagen and our ability to successfully capitalize on these opportunities; and manufacturing and product supply that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's press release and Oncology Innovation Day presentation dated February 29, 2024, as well as Pfizer's Annual Report on Form 10-K for the year ended December 31, 2023, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These materials are available on Pfizer's website at www.pfizer.com and Pfizer's SEC reports are also available on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.

This document is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. A number of our assets are partnered with rights varying by markets; please refer to slide 3 in Pfizer's Oncology Innovation Day presentation dated February 29, 2024 for additional information. All trademarks in this document are the property of their respective owners.



Pfizer Oncology Innovation Day Highlights

Appendix

CANCER DISEASE STATISTICS

Cancer remains one of the greatest health challenges of our lifetime

- ~2M new cancer cases in the US expected in 2024¹
- ~20M new cancer cases globally in 2022²
- ~10M deaths from cancer globally in 2022², and >600K deaths expected in the US this year¹

GENITOURINARY CANCERS

Prostate Cancer

- ~299K estimated new US cases in 2024¹ ; ~35K estimated US deaths in 2024¹
- ~\$14B estimated global market size in 2023³ ; ~\$26B forecasted global market size in 2030³

Castration resistant

- 1L metastatic ~51K US patients⁴
- Non-metastatic ~26K US patients⁴

Castration sensitive

- Metastatic ~30K US patients⁴
- Non-metastatic High Risk BCR ~16K US patients⁴
- TALAPRO-3 study population – epi est US ~8K HRRm patients⁵

Urothelial Cancer

- ~83K estimated new US cases in 2024¹ ; ~17K estimated US deaths in 2024¹
- ~\$5B estimated global market size in 2023³ ; ~\$17B forecasted global market size in 2030³
- ~18K US patients with locally advanced/metastatic urothelial cancer (includes bladder cancer)⁶
- ~28K US patients with muscle invasive bladder cancer⁷
- ~38K US patients (high risk) with non-muscle invasive bladder cancer⁶

Disitamab vedotin

- ~4K US patients with 2L HER2+ locally advanced / metastatic urothelial cancer⁶
- ~9K US patients with 1L HER2+ locally advanced / metastatic urothelial cancer⁶

THORACIC CANCERS

NSCLC

- ~280K estimated new US cases in 2023⁶ ; ~130K estimated US deaths in 2023⁵
- ~\$27B estimated global market size in 2023³ ; ~\$45B forecasted global market size in 2030³
- B6A-002 study population – estimated US epi ~50K⁹ 2-3L NSCLC

HNSCC

- ~67K estimated new US cases in 2023⁴ ; ~15K estimated US deaths in 2023⁸
- ~\$1.4B estimated global market size in 2023³ ; ~\$3B forecasted global market size in 2030³

HNSCC breakout^{9, 10}

- ~27K resectable LAD US
- ~18K unresectable LAD US
- ~16K 1L US
- ~5.4K 2L+ US

BREAST CANCER

- ~330K estimated new US cases in 2023⁸ ; ~44K estimated US deaths in 2023⁵
- ~\$30B estimated global market size in 2023³ ; ~\$60B forecasted global market size in 2030³

Breast Cancer: Collection of Multiple Diseases¹¹

- 65% - 70% HR+ HER2-
- 15 - 20% HER2+
- 10 - 15% TNBC

HR+/HER2-⁸

- ~20K = HR+/HER2- 2L mBC
- ~35K = HR+/HER2- 1L mBC
- ~220K = All HR+/HER2- early BC

HER2+ BC⁸

- ~10K = HER2+ 1L mBC
- ~35K = All HER2+ early BC

HEMATOLOGY

- Pfizer hematology products reached ~22K+ patients in 2023
- Pfizer’s product for cHL has reached more than ~55K US patients since approval
- More than 2x increase commercial sales team promoting Pfizer’s product for RRMM

Multiple Myeloma

- ~35K estimated new US cases in 2023¹² ; ~13K estimated US deaths in 2023¹³
- ~\$29B estimated global market size in 2023³ ; ~\$44B forecasted global market size in 2030³
- US epi ~18K relapsed/refractory multiple myeloma¹⁴
- US epi ~31K newly diagnosed multiple myeloma¹⁴

PFIZER’S MANUFACTURING FOOTPRINT AND SCALE

Extensive internal network enables agility and supports growth trajectory for additional launches to 2030 and beyond

- 10 manufacturing sites for oncology medicines on three continents
- 6x increase in ADC vial volume capacity¹⁵
- 7x Bioreactors¹⁵
- >100 countries

abi, abiraterone; BC, breast cancer; cHL, classical Hodgkin lymphoma; cis, cisplatin; CRC, colorectal cancer; ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; HER2-, HER2-negative; HR+, hormone receptor-positive; HRRm, homologous recombination repair mutation; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; MIBC, muscle-invasive bladder cancer; MM, multiple myeloma; mUC, metastatic urothelial carcinoma; NDMM, newly diagnosed multiple myeloma; NHT, novel hormonal therapy; PTM post-transplant maintenance; RRMM, relapsed or refractory multiple myeloma; TI, transplant-ineligible.

Please reference Pfizer’s Oncology Innovation Day presentation dated February 29, 2024 and Pfizer’s filings with the U.S. Securities and Exchange Commission (SEC) for additional information.

Footnotes:
1. American Cancer Society Facts & Figures Report (2024)
2. International Agency for Research on Cancer (IARC) Global Cancer Observatory
3. Clarivate (DRG) Market Forecast (2023)
4. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024), assuming 25% HRRm frequency
5. SEER
6. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024)
7. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024); reflects total miBC population, of which surgery eligible muscle invasive bladder cancer is a sub-population
8. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023)
9. Pfizer internal analysis
10. Cancer.net. <https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics>
11. American Cancer Society Breast Cancer Facts & Figures, 2022–2024; Patients within subtypes further categorized based on oncogenic mutations (e.g., BRCA, PIK3CA)
12. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023). (Total US MM Incidence)
13. US National Cancer Institute, Cancer Stat Facts: Myeloma.
14. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023); based on US incidence (symptomatic MM)
15. Compared to Seagen before acquisition

This document includes forward-looking statements about, among other things, Pfizer Oncology; Pfizer’s anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects, including Pfizer’s 2030 oncology goals; expectations for Pfizer’s product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity, expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines, and potential benefits; potential patients reached; potential portfolio composition; plans for and prospects of our acquisitions or dispositions and other business development activities; including our recent acquisition of Seagen and our ability to successfully capitalize on these opportunities; and manufacturing and product supply that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer’s press release and Oncology Innovation Day presentation dated February 29, 2024, as well as Pfizer’s Annual Report on Form 10-K for the year ended December 31, 2023, and Pfizer’s subsequent reports on Form 10-Q, including the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as Pfizer’s subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These materials are available on Pfizer’s website at www.pfizer.com and Pfizer’s SEC reports are also available on the U.S. Securities and Exchange Commission’s website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.

This document is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. A number of our assets are partnered with rights varying by markets; please refer to slide 3 in Pfizer’s Oncology Innovation Day presentation dated February 29, 2024 for additional information. All trademarks in this document are the property of their respective owners.